Peter C. Brandt is Director at REXAHN PHARMACEUTICALS, INC. (RNN). They have made 8 open-market trades across 5 companies since 2008, most recently 2025-12-22.
CIK 0001434099
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $1.5M since 2008, never a sale. Across 5 scored buys the stock is up 4.2% at ninety days, and 5.4 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 60% | 40% |
| Avg Move | +18.3% | +13.9% | +4.2% |
| Alpha | +18.7% | +15.4% | +5.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INAB | BUY | 2022-08-16 | 2022-08-18 | $1.90 | $400K | +45.3% | +28.9% | -19.5% |
| AUXL | BUY | 2012-02-28 | 2012-03-01 | $20.10 | $201K | N/A | N/A | N/A |
| RNN | BUY | 2011-09-08 | 2011-09-12 | $1.18 | $147K | -17.0% | -5.4% | -5.4% |
| EPOC | BUY | 2011-09-07 | 2011-09-09 | $9.78 | $142K | N/A | N/A | N/A |
| RNN | BUY | 2011-09-06 | 2011-09-08 | $0.97 | $24K | -17.0% | -5.4% | -5.4% |
| EPOC | BUY | 2011-09-06 | 2011-09-08 | $9.58 | $100K | N/A | N/A | N/A |
| NOVN | BUY | 2008-08-29 | 2008-09-02 | $12.39 | $248K | +40.1% | +25.7% | +25.7% |
| NOVN | BUY | 2008-05-13 | 2008-05-15 | $9.79 | $245K | +40.1% | +25.7% | +25.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.